anti-actin antibodies were from Sigma. Anti-pSIK2 Ser358 antibodies were generated in house as described previously ( 25 ) , orlistat was from Sigma, and D-14 C(U)-glucose was from Perkin Elmer.
Production of recombinant ApoA-I protein
A bacterial expression system consisting of pNFXex plasmid in Escherichia coli strain BL21(DE3) pLysS cells (Invitrogen) was used to generate the ApoA-I proteins as previously described ( 26, 27 ) . Primer-directed PCR mutagenesis was used to create the Arg(173)Cys substitution, and the mutation was verifi ed by dideoxy-automated fl uorescent sequencing. After protein purifi cation, tobacco etch virus protease was used to cleave off the His tag used for purifi cation using a Ni column. The samples were desalted into phosphate buffered saline, pH 7.4, 150 mM NaCl, concentrated with 10 kDa molecular mass cutoff Amicon Ultra centrifugal fi lter devices (Millipore), and stored at 4°C prior to use. Protein purity was confi rmed by SDS-PAGE with Coomassie blue staining and concentrations determined by Nanodrop, using molecular mass and extinction coeffi cient .
ApoA-I injection of C57BL/6J mice
C57BL/6J mice (Taconic), 10-to 12-week-old males, fed a high-fat diet (HFD) for 2 weeks ( 24 ), were injected intraperitoneally with either ApoA-I WT or ApoA-I Milano (20 mg/kg in phosphate-buffered saline, pH 7.4; control animals received NaCl) once daily for 6 days. Twenty-four hours after the last treatment, blood was sampled through vena saphena; blood glucose levels were measured using OneTouch Ultra2 (Lifescan); white blood cell (WBC) count was measured using a semiautomatic cell counter SYSMEX KX-21N; and insulin levels, cytokines, and FFAs (NEFAs) were assayed in serum. Adipose tissue was collected for Western blot analysis. The local animal ethics committee in Lund/Malmö approved all experiments.
Insulin assay
Serum samples were analyzed for insulin using a mouse insulin ELISA (10-1247-01; Mercodia AB, Uppsala, Sweden). All samples were analyzed in duplicate with a sample volume of 5 µl according to the supplier's instructions.
NEFAs
Serum samples were analyzed for NEFAs using a NEFA-HR ( 2 ) kit (Wako Chemicals GmbH, Neuss, Germany). All samples were analyzed in duplicate with a sample volume of 3.5 µl according to the supplier's instructions.
Cytokine analysis
Serum samples collected 24 h after injections were analyzed for TNF-␣ and interleukin 6 (IL-6) by an LSRII fl ow cytometer assay (BD Biosciences) ( 28 ) . Serum samples collected after completed treatment (day 7) were analyzed for TNF-␣ , IL-6, and IFN-␥ using an MSD Multi-Spot assay system Proinfl ammatory Panel 1 (mouse) kit. All samples were analyzed in duplicate according to the supplier's instructions.
Dual-energy X-ray absorptiometry
To determine the percentage of body fat, the mice were placed in a dual-energy X-ray absorptiometry (DEXA) scanner (PixiMouse, GE Healthcare), and body composition was measured.
Isolation and stimulation of primary adipose cells
Rat adipose cells were isolated from 36-to 40-day-old male Sprague Dawley rats, as described previously ( 29 ) . The cells were suspended (10% suspension) in Krebs-Ringer (KRH) medium HDL is mediated through ABCA1 ( 16 ) , but most likely also involves ABCG1 and other still unknown pathways ( 17 ) . Many studies have focused on the role of caveolae for cholesterol effl ux, with confl icting results ( 18, 19 ) . Le Lay et al. ( 18 ) proposed that interaction of ApoA-I with caveolin-1, the main structural caveolar protein, could occur without promoting cholesterol effl ux, which supports alternative, caveolae-independent pathways. In contrast, Sviridov et al. ( 19 ) suggested that ApoA-I regulates both caveolin-1 expression and intracellular cholesterol traffi cking to caveolae. Of interest, evidence suggests that ␤ -adrenergic stimulated lipolysis increases cholesterol effl ux, emphasizing a balance between triglyceride and cholesterol storage ( 20, 21 ) .
Together, considerable information is available about the systemic and the cellular effects of ApoA-I WT. However, there is less knowledge regarding the naturally occurring ApoA-I Milano variant, which contains a single point mutation that leads to an Arg(173)Cys substitution. Humans carrying the Milano variant have lowered HDL and increased circulating triglyceride levels, without increased risk for cardiovascular diseases ( 22 ) . The benefi cial properties of ApoA-I Milano have been suggested to be due to its effi ciency in mediating cholesterol effl ux and its potential to suppress infl ammation ( 23 ) . We have recently reported that acute treatment of insulin-resistant, diet-induced obese mice with recombinant Milano increases plasma glucose clearance and improves insulin secretion to the same extent as ApoA-I WT ( 24 ) . Thus, we decided to further characterize the effects of ApoA-I Milano in vivo and in vitro. Here, we report that injections of ApoA-I in insulin-resistant mice induce rapid weight loss and increase lipolysis without triggering an infl ammatory response. The effect on lipolysis was verifi ed in isolated rat adipose cells, in which both ApoA-I WT and Milano induced lipolysis, independent of cAMP/protein kinase A (PKA) and activation of hormone sensitive lipase (HSL) . Surprisingly, the Milano-stimulated effect was much greater compared with both ApoA-I WT and ␤ -adrenergic stimulated lipolysis. We report that Milano triggered cholesterol effl ux in both primary adipose cells and 3T3-L1 adipose cells, and we provide data that suggest that ABCA1 is not required to mediate these effects. The results propose a novel, but complex relationship at the cellular level between cholesterol effl ux, a redistribution of the intracellular cholesterol and triglyceride pools, and regulation of lipolysis independently of the canonical cAMP/PKA signaling pathway.
previously ( 32 ) . Three siRNAs targeting ABCA1 (sense: GGGUGGACGAGUUUCGGUAtt, antisense: UACCGAAACUCGUUCACCCag; sense: GGAACGGGUUACUAUCUGAtt, antisense: UCAGAUAGUAACCCGUUCCca; sense: CGAGGAUAACAACUACAAAtt, antisense: UUUGUAGUUGUUAUCCUCGta), and Silencer® Select Negative Control No. 1 (cat number 4390844) were purchased from Ambion® and were used at fi nal concentration of 0.5 nM each (1.5 nM total) on mature adipose cells (days [8] [9] . Forty-eight hours after electroporation, cells were stimulated with ApoA-I Milano (150 µg/ml), ApoA-I WT (150 µg/ml), isoproterenol (100 nM), or PBS for 2 h. After that, medium was collected for glycerol determination, and total RNA was collected using QIAzol™ reagent (Qiagen).
RNA preparation and quantitative real-time PCR
Analysis of gene expression in 3T3-L1 mature adipose cells transfected with ABCA1 siRNA and treated with ApoA-I Milano, ApoA-I WT, isoproterenol, or PBS was assessed by quantitative real-time PCR. Cells were lysed and homogenized in Qiazol™ lysis reagent, and total RNA was isolated using RNeasy® Mini Kit (Qiagen) according to the manufacturer's recommendations. Total RNA (1 g) was treated with DNase I (Invitrogen) enzyme and reverse transcribed using random hexamers (Invitrogen) and SuperScript™II (Invitrogen) RNaseH reverse transcriptase according to the manufacturer's recommendations. The cDNA was used in quantitative PCR reactions using TaqMan chemistry (Applied Biosystems) in an ABI 7900 Sequence Detection System. Relative abundance of mRNA was calculated using geometric averaging of TBP and Rps29 control genes.
Cholesterol effl ux
3T3-L1 adipocytes (days 7-12 of differentiation) cultured in 10 cm plates were harvested by trypsin/collagenase (type 1, Gibco 17100-017, fi nal concentration 1 mg/ml) digestion and then reseeded into 24-well plates. One day postseeding, cells were rinsed twice with PBS and then loaded with labeled cholesterol by culturing in DMEM containing 5% FBS, P/S, and 4 µCi/ ml 3 H-cholesterol (Perkin Elmer #NET139001MC, specifi c activity 19 Ci/mmol) for 24 h. To maximize the availability of free cholesterol for effl ux, 2 µg/ml of an inhibitor of ACAT (Sandoz58-035, Sigma) was also included. Subsequently, cells were rinsed twice with PBS and cultured for another 18 h in DMEM containing 0.2% BSA, P/S, and 2 µg/ml of the ACAT inhibitor, to enable equilibration of cellular cholesterol pools. Finally, cells were rinsed twice with PBS and then treated with ApoA-1 WT or Milano (or PBS as a control) at indicated concentrations for 3 h. Medium was collected and centrifuged at 14,000 g for 5 min to remove any fl oating cells, and the amount of labeled cholesterol was measured by scintillation counting. To normalize for potential differences in the amount of cholesterol loaded, cells were lysed and scraped in 0.1 M NaOH, a portion of the cell lysate was counted, and cholesterol effl ux was expressed as cholesterol in the medium/(cholesterol in the medium + cholesterol in cell lysates).
Isolated primary rat adipose cells were incubated with a BODIPY-cholesterol solution in MEM [0.05 mM BODIPY-cholesterol "Topfl uor" (Avantipolar lipids)], 0.2 mM unlabeled cholesterol, and 10 mM methyl-B-cyclodextrin (m ␤ CD), prepared according to ( 33 ) for 1 h at 37°C. The ratio of cells to BODIPYcholesterol solution was 1:2 (v/v), with a fi nal concentration of 1% BSA (w/v) and 200 nM adenosine. Cells were then washed three times with KRH medium without glucose and equilibrated for 1 h at 37°C. Uptake of BODIPY-cholesterol into adipose cells was confi rmed by confocal microscopy and/or by fl uorescence measurement of isopropyl alcohol extracted lipids. Prior to effl ux incubations, cells were washed three times with KRH medium without glucose, BSA, or adenosine, and then 50 µl cells containing 25 mM HEPES pH 7.4, 200 nM adenosine, 2 mM glucose, and 1% BSA (w/v) and stimulated as indicated in the fi gures. To stop incubations, cells were washed in KRH without BSA and subsequently lysed in a buffer containing 50 mM Tris/HCl pH 7.5, 1 mM EGTA, 1 mM EDTA, 1 mM sodium orthovanadate, 10 mM sodium-␤ -glycerophosphate, 50 mM sodium fl uoride, 5 mM sodium pyrophosphate, 0.27 M sucrose, 1% NP-40, 1 mM DTT, and complete protease inhibitor cocktail (1 tablet/50 ml) (lysis buffer). Lysates were centrifuged for 15 min at 13,000 g , 4°C, and protein concentrations were determined by Bradford. To obtain the lipid droplet fraction, the fat cakes following centrifugation were processed according to previously described method ( 30 ) . Briefl y, the fraction was recentrifugated, warmed to room temperature, and vortexed with SDS sample buffer. The sample was centrifuged for 15 min at 13,000 g , 4°C, and protein was extracted from the lipid droplet collected from beneath the fat layer. Mouse adipose cells from epididymal adipose tissue of caveolin-1 KO or C57BL/6J WT mice were isolated as described above, with KRH buffer containing 3% BSA. For adipose tissue lysates, intact tissue was homogenized with a polytron (Omni International TH) in lysis buffer and treated as above.
Lipolysis assay
To measure lipolysis, rat or mouse adipose cells [400 µl of a 5% (v/v) suspension] were suspended in KRH medium and treated with ApoA-I or isoproterenol as indicated in the fi gures (at 37°C, with shaking, 150 cycles/min). After 30 min, samples were placed on ice for 20 min, and 200 µl of the cell medium was subsequently removed for enzymatic determination of the glycerol content, as described previously ( 31 ) . The cells were washed twice with KRH medium without BSA and lysed in lysis buffer as described above.
Western blot
Cell lysates (10 µg total protein) were heated at 95°C for 2 min in lithium dodecyl sulfate sample buffer, and subjected to PAGE on precast BioRad gradient gels and electrotransfer to nitrocellulose membrane. Membranes were blocked for 30 min in 50 mM Tris/ HCl pH 7.6, 137 mM NaCl, and 0.1% (w/v) Tween-20 (TBS-T) containing 10% (w/v) milk. The membranes were then probed with indicated antibodies in TBS-T containing 5% (w/v) milk or 5% (w/v) BSA, for 16 h at 4°C. Detection was performed using horseradish peroxidase-conjugated secondary antibodies and the enhanced chemiluminescence reagent. The signal was visualized using a LI-COR Image camera, and band intensities were quantifi ed using Licor Imaging software (Licor).
Culture and differentiation of 3T3-L1 adipose cells
3T3-L1 fi broblasts were cultured at subconfl uence in DMEM medium containing 10% FCS (v/v) and 1% penicillin/streptomycin (v/v) at 5% CO 2 in 37°C. Two days postconfl uence (designated as day 0), cells were incubated with DMEM medium containing 10% FCS (v/v) and 1% penicillin/streptomycin (v/v) supplemented with 0.5 mM 3-isobutyl-1-methylxanthine, 10 g/ml insulin, and 1 M dexamethasone for 48 h. After that, the medium was changed to DMEM supplemented with 10 g/ml insulin for 48 h, cells were hereafter cultured in DMEM medium containing 10% FCS (v/v) and 1% penicillin/streptomycin (v/v), and culture medium was changed every second day. Experiments were performed on days 8-11 after the initiation of differentiation (day 0), at which differentiation rate was typically 80-90%.
siRNA silencing
Mature 3T3-L1 adipose cells (8-9 days post differentiation) were transfected with siRNA by electroporation as described injection/day of either ApoA-I WT, ApoA-I Milano (20 mg/kg), or saline (NaCl), for 6 days. Twenty-four hours following the fi rst injection, both ApoA-I WT-and Milanotreated mice demonstrated a rapid reduction in body weight ( Fig. 1A ) . After repeated injections, ApoA-I Milanotreated mice displayed a signifi cant reduced body weight throughout the entire treatment period, both compared with ApoA-I WT-and saline-treated animals ( Fig. 1A ). There were no signifi cant changes comparing ApoA-I WTand saline-treated mice over the entire time period. Animals treated with Milano, but not WT, displayed a signifi cantly decreased body fat mass as determined by DEXA scan ( Fig. 1B ) . Serum analysis of fed animals showed no changes in NEFA, glucose, or insulin levels ( Fig. 1C-E ) comparing Milano-, WT-, or saline-treated animals. To examine if the ApoA-I treatment had affected the rate of lipolysis in adipose cells, we isolated primary adipose cells 24 h after the last injection and measured glycerol release into medium. Interestingly, cells isolated from both ApoA-I WT-and Milano-treated mice displayed increased lipolysis compared with cells isolated from saline-treated animals, both nonstimulated and in vitro stimulated with a ␤ -adrenergic receptor agonist (isoproterenol, 10 nM) ( Fig. 1F ). Western blot analysis of epididymal adipose tissue excised 24 h after the last treatment showed that the injected ApoA-I protein was present in adipose tissue ( Fig. 1G ). However, no consistent changes in HSL expression level or activation (HSL pS563) were detected ( Fig. 1G ) . Interestingly, protein levels of both caveolin-1 and caveolin-2, known to be involved in intracellular cholesterol traffi cking ( 34 ), were upregulated in adipose tissue from ApoA-I-treated mice ( Fig. 1G ) .
To examine if the ApoA-I protein itself or the repeated injections caused an immunologic response that could contribute to the reduced body weight, we analyzed blood and serum collected the day after the last treatment. Whole blood analysis showed that the number of WBCs and lymphocytes were unchanged when comparing Milano-, WT-, and saline-injected animals ( Fig. 1H ) . Further, we detected no changes of either TNF-␣ , IL-6, or IFN-␥ levels ( Fig. 1I ) . The animals did not display any signs of immunologic response (i.e., hunching or reluctance to move).
To investigate if reduced food intake contributed to decreased body weight gain, food consumption was measured in a separate study in which daily injections were made for 2 days. For comparison, groups of mice received either ApoA-I WT (20 mg/kg), Milano (20 mg/kg), BSA (20 mg/kg), or NaCl. ApoA-I treatment reduced food intake, and this effect was more pronounced following Milano treatment, compared with ApoA-I WT, even though the animals received the same dose of ApoA-I protein ( Fig.  1J ) . Because the main weight loss of ApoA-I-treated animals occurred after the fi rst injection ( Fig. 1A ) , a separate serum analysis was made at this time point. TNF-␣ and IL-6 levels analyzed in serum collected from NaCl, BSA-, ApoA-I WT-or Milano-injected animals were below the detection limit ( р 10 pg/ml), whereas the positive control (10 µg lipopolysaccharide for 90 min) showed markedly elevated levels of TNF-␣ and IL-6 ( Fig. 1K ) .
were added to 500 µl medium (as previously described), containing the cholesterol acceptors. After incubation at 37°C for the indicated times, medium was carefully collected from underneath the cells, and cholesterol effl ux quantifi ed by measuring fl uorescence (extinction/emission 482 nm/510 nm), in triplicate, using a Victor (Wallac) plate reader.
ApoA-I labeling in adipose cells for immunofl uorescence microscopy
ApoA-I Milano or WT were conjugated to ATTO-565 N -hydroxysuccinimide-ester (Atto-tech, Siegen, Germany) according to the manufacturer's instructions. In the experiment, ATTO-565-conjugated ApoA-I was used at 10 µg/ml, and nonfl uorescent ApoA-I (WT and Milano) was used at 140 µg/ml, making the total ApoA-I concentration 150 µg/ml. Primary rat adipose cells were pretreated with or without glybenclamide (250 µM) for 30 min at 37°C. ApoA-I, WT or Milano (ATTO-565 conjugated and nonfl uorescent), was added in the concentrations described above and incubated for 30 min at 37°C. Cells were washed two times with KRH buffer without BSA, followed by fi xation in 4% paraformaldehyde for 6 min, washed two times in PBS, blocked, and permeabilized in KRH buffer with 0.1% saponin for 30 min. Primary mouse ABCA1 antibody at a concentration of 2 µg/ml was added and incubated for 1 h. After washing, cells were resuspended in buffer containing Alexa Fluor 488 goat anti-mouse IgG secondary antibody (Alexa Fluor, Molecular Probes, Life Technologies). All steps during cell preparation were performed at room temperature.
TIRF imaging and image analysis
Imaging was performed using a Nikon Ti-E eclipse microscope with a 100× Apo Total internal refl ection fl uorescence (TIRF) differential interference contrast oil immersion objective with an NA of 1.49 (Nikon Instruments Inc.), an iXon Ultra DU-897 EMCCD camera (Andor Technology Ltd.), and 488 and 561 laser lines (Melles Griot Inc. and Coherent Inc.) with matching fi lter sets. A TIRF angle corresponding to a TIRF-zone depth of ‫ف‬ 63 nm into the specimen was used during imaging. All images were identically subjected to both background subtraction and threshold settings. Mean intensity values were calculated for region of interest, covering the total membrane surface of the cells in TIRF zone, using NIS Elements, version 4.30.02 (Laboratory Imaging). For each experiment, ‫ف‬ 30 cells/condition/experiment were analyzed.
Statistical analysis
All data are displayed as mean ± SEM. Analysis was performed by Student's t -test and two-way ANOVA ( Fig. 1A ) using GraphPad Prism 6 (GraphPad Software Inc.) software. Signifi cance was determined according to the following: * P р 0.05, ** P р 0.01, *** P р 0.005, and **** P р 0.0001.
RESULTS

ApoA-I Milano treatment induces rapid weight loss and increased lipolysis
Previous studies have reported an association between increased HDL levels and decreased body weight (3) (4) (5) , and therefore, we wanted to investigate the effect of repeated injections of ApoA-I protein on body weight and composition in an insulin-resistant animal model. Animals were fed an HFD for 2 weeks, followed by one intraperitoneal /kg) , or saline (NaCl), during 6 days (n = 6-11 animals/group). Body weight was monitored daily during the treatment and 24 h after the last injection (day 0 fi rst injection, day 5 last injection) (A). Data presented in B-I were collected 24 h after the last treatment (n = 6-11 animals/group); fat mass determined by DEXA body scan (% body fat mass) (B), serum NEFA (mM) (C), blood glucose (mM) (D), and serum insulin (µg/l) (E). Adipose cells were isolated from epididymal fat tissue, and lipolysis was measured by analyzing glycerol release into medium, either nonstimulated or isoproterenol stimulated (10 nM, 30 min ( Fig. 2C ) . Preincubation with propranolol, a ␤ -adrenergic receptor antagonist, abolished isoproterenol-induced HSL pSer563 and perilipin pSer522 activation but had no effect in either WT-or Milano-stimulated cells ( Fig. 2C ) . Also, preincubation with propranolol inhibited isoproterenol-induced glycerol release but had no effect on the Milano-stimulated release (supplementary Fig. 1 ). Western blot analysis showed that isoproterenol, but not Milano, triggered the cAMP/PKA pathway, as detected by phospho-PKA substrate antibody, as well as phosphorylation of the known PKA substrate SIK2 (pSer358) (supplementary Fig. 2) ( 25 ) . Also, the level of adipose triglyceride lipase expression was unchanged in both ApoA-I Milano-and isoproterenol-treated cells compared with control cells (supplementary Fig. 2) ( 36 ) .
Because the glycerol assay measures the accumulated glycerol release during 30 min, we also examined shorter time points to investigate if there was a rapid, possibly transient phosphorylation/activation of HSL and perilipin in response to ApoA-I Milano. Already after 5 min of incubation with isoproterenol an increased phosphorylation of perilipin pSer522 and HSL pSer563 was observed ( Fig.  2D ) . However, incubation with Milano for 5 min did not induce the phosphorylation of these targets. Phosphorylation of perilipin pSer522 was further monitored at time points 15 and 30 min without any changes compared with the 5 min time point ( Fig. 2D ) . To investigate the possibility that ApoA-I induced phosphorylation of perilipin on sites other than Ser522, we analyzed perilipin immunoprecipitates using a number of kinase consensus antibodies (14-3-3 binding motif, pPKA-, pPKB-, pPKC-, pCDK-, and pMAPK/CDK substrate). Isoproterenol induced a clear phosphorylation of perilipin on PKA consensus sites, whereas Milano failed to increase the phosphorylation as measured with this or any of the other consensus antibodies (data not shown).
To further test if ApoA-I was dependent on HSL activation, primary adipose cells were preincubated with orlistat, a lipase inhibitor, followed by incubation with either Milano or isoproterenol . The lipase inhibitor reduced the isoproterenol-stimulated lipolysis but had no effect on Milano-stimulated glycerol release ( Fig. 2E ) . In addition to the classical lipolytic pathway, low-grade infl ammation ( 35 ) and endotoxins ( 37 ) have been shown to induce lipolysis through different pathways, both leading to activation of HSL. Our data suggest that ApoA-I-induced lipolysis is independent of HSL activation, and therefore, it is unlikely that the ApoA-I-generated effect is mediated through the infl ammatory pathways.
In summary, injections of Milano led to an initial rapid weight loss, leading to a signifi cantly reduced body weight after repeated treatments compared with WT-treated mice. The fact that all ApoA-I-treated mice displayed reduced body weight could in part be explained by decreased food intake. These fi ndings are in line with previous reports in which increased ApoA-I WT expression/levels were associated with decreased body weight and fat mass, and the fact that human carriers of the Milano variant have a favorable metabolic profi le. Because the cytokine profi le, WBCs, and lymphocytes were unaltered, it is unlikely that these effects were caused by an infl ammatory response that otherwise potentially could contribute to an increased lipolytic activity ( 35 ) . Rather, our interpretation is that the rapid weight loss is due to increased circulating ApoA-1 levels, which affect peripheral tissues as well as food intake.
ApoA-I Milano induces lipolysis in vitro independently of HSL and perilipin phosphorylation
Our fi nding of increased lipolysis in adipose cells from ApoA-I-treated mice ( Fig. 1F ) could be due to systemic factors other than ApoA-I. Because earlier studies in vitro have shown that adrenergically stimulated lipolysis could induce cholesterol effl ux ( 20, 21 ), we wanted to examine if ApoA-I affected nonstimulated lipolysis using an in vitro primary rat adipose cell model. Interestingly, we found that 30 min incubation with either ApoA-I WT or Milano protein (both nonlipidated) stimulated lipolysis in the absence of ␤ -adrenergic stimulation ( Fig. 2A ) . Surprisingly, Milano induced a signifi cantly higher glycerol release compared with WT at the same concentration. As a positive control, cells were incubated with isoproterenol ( Fig.  2A ) . In separate experiments, we tested and verifi ed that the Milano-induced glycerol release was dose dependent, shown in Fig. 2B . These results suggest that both ApoA-I WT and the Milano variant exert adipose cell-specifi c effects leading to increased lipolysis, and that Milano is much more effective at the same concentration.
To explore the signaling pathways involved in mediating ApoA-I-stimulated lipolysis, we performed Western blot analysis of adipose cell lysates generated after incubation. As was expected, ␤ -adrenergic stimulation resulted in phosphorylation of both perilipin (pSer522) and HSL (pSer563), shown in Fig. 2C . However, in line with the data obtained in vivo ( Fig. 1G ) , we detected no ApoA-I WT-or Milano-induced phosphorylation of either perilipin pSer522 or HSL pSer563 ( Fig. 2C ) . Further, ApoA-I did not alter the level of HSL pSer565, a suggested AMP-activated protein kinase site was collected and subjected to Western blot analysis to determine caveolin-1, caveolin-2, and HSL protein expression levels; phosphorylation of HSL pS563; and presence of ApoA-I Milano using an ApoA-I-specifi c antibody (n = 4-5 animals/group) (G). Whole blood was analyzed to determine WBC count and lymphocytes (Lym) (×10 9 /l) (H). Serum collected the day after last treatment was analyzed for levels of TNF-␣ , IL-6 (left y-axis, pg/ml), and IFN-␥ (right y-axis, pg/ml) (I). Food consumption (g/mouse/day) was measured per cage (5 animals/cage). Data displayed as mean from 2 days (J). Serum collected 24 h after the fi rst injection was analyzed for levels of TNF-␣ and IL-6 (pg/mol); serum from mice treated with 10 µg lipopolysaccharide for 90 min was used as a positive control (n = 5 animals/group) (K). Data in A-K are presented as mean ± SEM. * P р 0.05, ** P р 0.01, *** P р 0.0005, and **** P р 0.0001. Together, these data support the hypothesis that cholesterol effl ux could initiate lipolysis, even though M ␤ CDstimulated lipolysis at least partially is mediated through an HSL-dependent pathway. There is a tightly regulated balance of intracellular cholesterol and triglyceride pools within the cell, and removal of cholesterol from the pool associated with the lipid droplet could be suffi cient to promote lipolysis without lipase activation.
ApoA-I WT and Milano stimulate glycerol release independently of ABCA1
In order to examine if Milano-stimulated glycerol release was dependent on ABCA1, a receptor known to be involved in cholesterol effl ux and formation of HDL particles ( 39 ), we used a well-described inhibitor, glybenclamide, which suppresses ABCA1 ATPase activity and thus inhibits cholesterol effl ux ( 40 ) . However, preincubation of rat adipose cells with glybenclamide (250 µM) prior to ApoA-I WT or Milano incubation did not inhibit ApoA-I-stimulated lipolysis ( Fig. 3A ) . To verify this fi nding, we applied siRNA silencing of ABCA1 in differentiated 3T3-L1 cells. The effi ciency of ABCA1 knock down was determined at the mRNA level using real-time PCR ( Fig. 3B ) . Next, we compared the effect on glycerol release using both ApoA-I WT and the Milano variant in ABCA1-defi cient 3T3-L1 cells. Silencing of ABCA1 did not affect isoproterenol-, ApoA-I WT-, or Milano-induced lipolysis ( Fig. 3C ) . Indeed, similar to our fi nding in rat adipose cells, both ApoA-I WT and Milano induced glycerol release in 3T3-L1 cells ( Fig. 3C ) . Again, the increase in lipolysis was much greater following Milano stimulation than with the same concentration of ApoA-I WT. To further test if ABCA1 was involved in binding of ApoA-I to the cell surface, primary adipose cells were incubated with fl uorescently labeled ApoA-I (either WT or Milano; ApoA-I-ATTO-565). The distribution of ApoA-I-ATTO-565 and ABCA1, using an ABCA1 specifi c antibody, was analyzed by TIRF microscopy at a zone depth of 63 nm into the cells, thus excluding most of the labeling distributed in the cytosolic compartment. Both ABCA1 and ATTO conjugated In summary, the data show that both ApoA-I Milano and WT trigger lipolysis in primary adipose cells without an increase in the classical cAMP/PKA pathway or any apparent phosphorylation/activation of either perilipin or HSL.
ApoA-I Milano triggers cholesterol effl ux in adipose cells
To our knowledge, there are no previous reports that ApoA-I/HDL can independently induce lipolysis. Rather, lipolysis has been shown to induce cholesterol effl ux ( 20, 21 ) . In addition, the cellular effects of the Milano variant have been poorly investigated. Because the data presented herein did not involve the common or infl ammatory lipolytic pathway, we wanted to test if the ApoA-I Milano variant could stimulate cholesterol effl ux using a 3T3-L1 adipose cell model. Cells preloaded with cholesterol were incubated with either WT or Milano (3 h) followed by analysis of cholesterol content in the medium. Both WT and Milano induced a signifi cant cholesterol effl ux, shown in Fig. 2F . We also tested the ability of Milano to stimulate cholesterol effl ux in primary adipose cells. M ␤ CD (20 mM) was used as a positive control and induced a ‫ف‬ 2-fold increase of cholesterol effl ux ( Fig. 2G ). In line with previous reports using ApoA-I WT or reconstituted HDL particles, we found that Milano induced cholesterol effl ux ‫ف‬ 1.4-fold compared with nonstimulated cells ( Fig. 2G ). This effect was modest but reproducible and in the same range as previously reported using ApoA-I WT in adipose cells ( 38 ) . The ability of Milano to remove cholesterol could contribute to the mechanism through which it exerts an effect on lipolysis. Indeed, we discovered that M ␤ CD also stimulated lipolysis in a dose-dependent manner ( Fig. 2H ) . Distinct from Milano, however, M ␤ CD stimulated activation of HSL ( Fig. 2I ) . To examine if there was a cellular uptake of Milano, adipose cells were preincubated with either Milano or isoproterenol, followed by subcellular fractionation to obtain a cytosolic and a lipid droplet fraction. Interestingly, we found Milano to be associated with the lipid droplet ( Fig. 2J ) . As a positive control, we detected both HSL and perilipin in the lipid droplet fraction ( Fig. 2J ) .
determine total protein expression levels of HSL and perilipin, ␤ -actin, phosphorylation of HSL pSer563, HSL pSer565, and perilipin pSer522. The graph represents quantifi cation of Western blot data (three independent experiments) with representative Western blots shown below (C). Cells were incubated with Iso (10 nM) or Milano (150 µg/ml) for time points indicated in the fi gure (5-30 min). Cell lysates were prepared and subjected to Western blot and analyzed to determine total protein expression levels of HSL and perilipin, and phosphorylation of HSL pSer563, and perilipin pSer522, samples run in duplicates, n = 3 independent experiments. The fi gures show representative Western blots. (D) Primary adipose cells were preincubated with or without orlistat (100 µM, 45 min), followed by 30 min incubation with either Milano (150 µg/ml) or Iso (10 nM). Glycerol release was measured in medium (% of Milano), n = 3 independent experiments (E). Differentiated 3T3-L1 cells were preloaded with 3 H-cholesterol (3 h) and treated with PBS (control) or ApoA-I WT or Milano (concentrations indicated in the fi gure, 50-150 µg/ml). Cholesterol effl ux was measured into the medium [fold of control (ctr)], n = 4 independent experiments (F). Isolated adipose cells were preloaded with cholesterol (1 h) followed by treatment with either PBS, Milano, or M ␤ CD (20 mM) as a positive control. Cholesterol effl ux was measured into the medium (fold of ctr), n = 3-5 independent experiments (G). Adipose cells were treated with M ␤ CD (concentration indicated in fi gure, 2-10 mM) for 90 or 30 min, followed by glycerol release measurement in the medium, expressed as µmol/90 min/mol in (H) and µmol/30 min/mol (I). Cell lysates of stimulated cells were subjected to Western blot to determine ␤ -actin expression and phosphorylation of HSL pSer563 (I). Adipose cells were left untreated (Ctr) or incubated with Milano (150 or 300 µg/ml) for 60 min or Iso (10 nM, 5 or 60 min), followed by homogenization and subcellular fractionation to provide cytosol and lipid droplet fractions, which were subjected to Western blot to determine distribution of ApoA-I, HSL, perilipin, HSL pSer563, and perilipin pSer522. Representative blots shown in fi gure, n = 3 independent experiments (J). Data in A-C and E-I presented as mean ± SEM. * P р 0.05, ** P р 0.01, *** P р 0.0005, and **** P р 0.0001 . Caveolae are implicated in different cellular processes such as signal transduction and endocytosis ( 34, 41 ) , but their specifi c role in cholesterol effl ux is still debated ( 18, 19 ) . Because almost 50% of the adipose cell surface consists of cholesterol-enriched caveolar membrane, and our in vivo data showed increased caveolin-1 levels in ApoA-I-treated mice ( Fig. 1G ) , we wanted to examine if these structures were required for Milano-induced lipolysis. For this, we made use of adipose cells from caveolin-1-defi cient mice, which as a consequence lack caveolae. We found that isoproterenolstimulated lipolysis was reduced in cells from caveolin-1 KO with either WT or Milano were found to be distributed as distinct puncta ( Fig. 3D ) . Quantifi cation of the ApoA-I-ATTO-565 signal in the TIRF zone showed that preincubation with glybenclamide (250 µM) signifi cantly reduced the amount of both ApoA-I WT and Milano bound ( Fig.  3E ) . In contrast, the amount of ABCA1 detected at the surface was not altered ( Fig. 3F ) . Together, our data suggest that ABCA1 has the capacity to bind both ApoA-I WT and Milano but is not required for mediating Milano-or ApoA-I WT-induced glycerol release in the two different adipose cell models tested herein. at the site of the plasma membrane but also at the intracellular site of cholesterol storage. Indeed, it has been reported that cholesterol effl ux from mature human adipose cells is mediated independently of cAMP but is dependent on intact intracellular cholesterol traffi cking, thus supporting our data suggesting cholesterol removal from the lipid droplet ( 45 ) . Also, our finding of a somewhat surprising robust M ␤ CD-induced glycerol release supports the concept of a balance between cholesterol and triglycerides. Previous microscopy analysis revealed that both M ␤ CD and ApoA-I WT promoted redistribution of lipid droplet-associated cholesterol ( 46 ) . In addition to the classical lipolytic pathway, low-grade infl ammation has been suggested to stimulate lipolysis through the inhibitor of nuclear factor B kinase subunit beta/nuclear factor B pathway ( 35 ) , and endotoxins to induce lipolysis through Toll-like receptor 4 ( 37 ), both pathways leading to HSL activation. Our data of ApoA-I-mediated lipolysis appear to be independent of HSL activation, and taken together with the lack of a systemic infl ammatory response, this suggests the effects of ApoA-I we observed, both in vivo and in vitro, are independent of infl ammatory-mediated pathways.
The proposed mechanism underlying the extremely effi cient cholesterol removal ability of the Milano variant in humans is based on its altered structural properties, with an additional cysteine bridge favoring dimerization with ApoA-II, another HDL-associated lipoprotein ( 47 ) . In our in vitro system, the Milano variant was much more potent in triggering lipolysis than ApoA-I WT, and thus, unless adipose cells secrete ApoA-II, the greater effect of Milano versus WT is independent of the structural interaction with ApoA-II. Still, other ApoA-I Milano-specifi c structural properties could very well account for the increased efficiency in stimulating lipolysis.
ABCA1 is a central component in the early phase of reverse cholesterol transport. Our data suggest that ABCA1 is involved in binding Milano but is not required for mediating ApoA-I WT-or Milano-stimulated lipolysis. Future image analysis could be helpful for verifying the subcellular location of Milano and to explore potential cholesterol redistribution from the lipid droplet that in turn could lead to increased lipolysis. Ultimately, live cell imaging of both lipolysis and cholesterol traffi cking could provide useful knowledge about substrate traffi cking within the cell, both in the normal and in the obese state. Because ABCA1 inhibition did not reduce Milano-induced lipolysis, alternative pathways are likely to be involved, for example ABCG1 or possibly passive diffusion, even though the concentration of ApoA-I used herein should act via receptor-specifi c uptake ( 48 ) .
Caveolin-1-defi cient mice lacking caveolae are resistant to diet-induced obesity and have reduced adipose tissue mass and elevated circulating triglycerides and FFA levels. In agreement with our present study, these mice also show a blunted lipolytic response to ␤ -adrenergic receptor stimulation ( 42, 49, 50 ) , suggesting defects in lipid storage and adipogenesis. In the presence of ApoA-I Milano, we found a similar increase of lipolysis in adipose cells isolated from mice compared with control cells, which is in agreement with previous fi ndings by Cohen et al ( 42 ) (supplementary  Fig. 3) . However, ApoA-I Milano induced glycerol release to the same extent in cells lacking caveolin-1 compared with control cells. These fi ndings further support the notion that stimulation of adipose cell lipolysis by ApoA-I Milano is independent of classical lipolytic signaling pathways.
DISCUSSION
Apolipoproteins are well known for promoting cholesterol effl ux from the vascular wall but have also been shown to promote cholesterol effl ux in adipose cell models ( 43, 44 ) . Considering the limited de novo synthesis of cholesterol in adipose cells, it is reasonable to believe that cholesterol effl ux from the adipose cells will affect their function and thus have an impact on whole-body glucose homeostasis ( 43 ) . Here we wanted to examine the adipose cell-specifi c effect of Milano, a naturally occurring variant of ApoA-I. Remarkably, we found that treatment of ApoA-I Milano and ApoA-I WT, the latter used as a control throughout the experiments, rapidly induced weight loss in a diet-induced insulin-resistant mouse model. We also found an increased lipolytic activity in adipose cells isolated from the in vivo ApoA-I-treated animals, with no evidence of an elevated systemic infl ammatory response, which suggests that ApoA-I exerts a direct effect on adipose cells. This is of great interest because obesity, with altered adipose function, is one of the main risk factors for several metabolic diseases.
Further, we herein report that both ApoA-I WT and the Milano variant promoted cholesterol effl ux from adipose cells, which is in line with previous reports using lipid-free ApoA-I WT or ApoA-I-containing HDL ( 19, 21 ) . We also present novel fi ndings of both ApoA-I WT-and Milanostimulated glycerol release, independently of ␤ -adrenergic stimulation, in two different adipose cell models. Compared with WT, Milano exerted a markedly stronger effect on lipolysis but not on cholesterol effl ux, demonstrating that there could be different mechanisms involved; such alternative mode of action could account for the well-described effect of Milano on vascular wall function ( 22 ) .
The lack of HSL and perilipin phosphorylation in response to Milano suggests that increased cholesterol effl ux from the adipose cell may instead alter the protection of the lipid droplet surface and thus allow increased lipase activity without changes in phosphorylation. Previous studies have described a balance between lipolysis and cholesterol effl ux in adipose cells, where ␤ -adrenergic stimulation of lipolysis in 3T3-L1 adipose cells increased cholesterol effl ux to HDL ( 20, 21 ) . However, in the latter study, presence of HDL did not itself initiate effl ux of cholesterol from adipose cells. We hypothesize that the cholesterol effl ux induced by Milano will alter the cholesterol distribution within the lipid droplet, diminishing the protection against lipolysis. We also observed that Milano was associated with the lipid droplet, and endocytosis of ApoA-I Milano could potentially lead to cholesterol removal not only WT and caveolin-1-defi cient mice. We therefore conclude that the Milano-induced effect was mediated independently of caveolin-1 and caveolae. These data suggest that the increased protein expression of caveolin-1 and caveolin-2 detected in adipose tissue from Milano-treated mice may be secondary to increased cholesterol effl ux within the cell.
In conclusion, we have provided evidence that in primary adipose cells, the ApoA-I Milano variant mediates cholesterol effl ux and triggers lipolysis independently of ␤ -adrenergic stimuli. ApoA-I WT also stimulated lipolysis, but to a much lesser degree than Milano. These adipose cell-specifi c effects may contribute to reduced total body fat mass and possibly improve systemic insulin sensitivity, and, at least to some extent, account for the metabolic profi le of human ApoA-I Milano variant carriers.
